Executive Director, Biden Cancer Initiative
Executive Director, White House Cancer Moonshot Task Force
Chief of Domestic Policy under Vice President Al Gore
Pfizer, Former Director of Worldwide Policy
Mr. Simon serves as President of the Biden Cancer Initiative at the Biden Foundation. Previously, he was the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. As Executive Director, Greg assembled and led a team of eight professionals to support the work of the Vice President in developing and promoting the goals of the Cancer Moonshot in numerous meetings and presentations and to coordinate the work of the Task Force comprised of twenty cabinet and sub-cabinet offices.
Over the past ten months Greg and his team worked across the Task Force, academia and the private sector to create over seventy innovative collaborations. On October 17th, 2016, Greg joined the Vice President to present the Cancer Moonshot reports to President Obama in an Oval Office briefing. On December 7, 2016, the passage of the 21st Century Cures Act provided $1.8 billion for the Cancer Moonshot over the next seven years.
In his career, Greg has held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, was a senior strategy consultant to a variety of international technology CEO’s, co-founded and led FasterCures and the Melanoma Research Alliance, was the Senior Vice President at Pfizer for worldwide policy and public engagement and was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.
Greg came to Washington, DC in 1985 as General Counsel and then Staff Director of the Investigations Subcommittee of the House of Representatives’ Science, Space and Technology Committee. During his years with the Science Committee, Greg organized a series of investigatory hearings on biotechnology policy and was involved in hearings and investigations related to NASA and the Challenger explosion, scientific misconduct, the use of human biological materials in research and the artificial heart program.
Mr. Simon served as Sen. Gore's Legislative Director from 1991 to 1993 before joining him in the White House as his Chief Domestic Policy Advisor. He was the lead staffer for the Clinton-Gore Administration for development and passage of the Telecommunications Reform Act of 1996 as well as development of the National and Global Information Infrastructure. He represented the Vice President on the National Economic Council, helped negotiate the US-Russia agreement on the International Space Station and oversaw a number of key initiatives, including programs at the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Human Genome Project. He was also instrumental in crafting the regulatory framework that is now the foundation for the biotechnology industry.
Following his White House service Greg was CEO of Simon Strategies and provided strategic advice to CEO’s of major firms such as Sony, Cisco, Netscape, Motorola, Sega and AOL.
Starting in 2003, Mr. Simon worked with Mike Milken to co-found FasterCures/The Center for Accelerating Medical Solutions. FasterCures has become an organization valued and recognized for catalyzing systematic change in the process of discovery and development and of new therapies for deadly and debilitating diseases.
Under Greg’s leadership, FasterCures created the FasterCures Philanthropy Advisory Service, with funding from the Robert Wood Johnson Foundation and the Bill & Melinda Gates Foundation. This initiative accelerates and increases the flow of philanthropic support to nonprofit medical research organizations by providing in-depth data on the methods, goals, and potential impacts of nonprofit medical research organizations engaged in specific disease areas. He also created The Research Acceleration and Innovation Network (TRAIN) to promote innovation in disease research and to support the activities of organizations engaged in cutting-edge research.
While at FasterCures Greg co-founded the Melanoma Research Alliance with Leon and Debra Black.
From 2009-1012 Simon was Senior Vice President for Worldwide Policy and Patient Engagement at Pfizer, Inc. He led a global team of professionals in: 1) worldwide government policy, 2) science policy, 3) economic policy and research, and 4) international policy. He advised the CEO on the company’s efforts in Healthcare Reform. He also focused on engaging patients more productively in research and clinical trials and on helping Pfizer develop policies, practices, and medical solutions to improve health, happiness and productivity.
Prior to becoming Executive Director of the Cancer Moonshot, Greg was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Poliwogg’s first index, the Poliwogg Medical Breakthroughs Index, was the basis for the best performing health Exchange Traded Fund, “SBIO,” in 2015.
The journal Nature Medicine named Greg one of “Ten People to Watch” in health care policy, noting that he was among “a handful of influential people who quietly keep the wheels of biomedical science turning.” In 2010 he received the Genetic Alliance’s “Art of Advocacy” award. In May 2011 Greg was invited to be the second lecturer in the Constantin Spiegelfeld Lecture series of the Research Center for Molecular Medicine of the Austrian Academy of Sciences. He is the recipient of the Arab American Institute’s 2017 Najeem Halaby Public Service Award established by Queen Noor in memory of her father. He is a regular presenter at the Milken Institute Global Conference, the OECD, the Washington Campus (a nonprofit educational institution in Washington, D.C.) and at health conferences and academic institutions around the country.
He received his law degree from the University of Washington in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas.
JAMES P. ALLISON, PHD
2018 Nobel Laurate
Partner, Apricity Health
Olga Keith Wiess Distinguished University Chair for Cancer Research, MD Anderson
Director of the Parker Institute for Cancer Research
Executive Director of the Immunotherapy Platform, MD Anderson Cancer
Dr. James Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
STEVEN M. FERGUSON, CLP
Deputy Director and Chair, Licensing and Entrepreneurship, NCI
Steven M. Ferguson currently serves as the Deputy Director, Licensing and Entrepreneurship. Prior to joining NIH Office of Technology Transfer in 1990, Mr. Ferguson served in marketing and management positions in biomedical firms subsequent to being a scientist at the National Cancer Institute. His healthcare experience has also included work as Director of Marketing and Public Relations for a rural 70-bed hospital. Registered to practice before the USPTO and a Certified Licensing Professional (CLP), Mr. Ferguson also holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor’s Degree in Chemistry (Case Western Reserve University). Mr. Ferguson has been an economic reviewer for Maryland Industrial Partnerships (MIPS) as well as the Advanced Technology Program (ATP) grant programs and is an instructor for both the USDA Graduate School and the NIH FAES Graduate School where he is also the department chair for the new Certificate in Technology Transfer Program. Mr. Ferguson was also the Susan T. and Charles E. Harris Visiting Lecturer at the Watson School of Biological Sciences at the Cold Spring Harbor Laboratory and has published articles on licensing and technology transfer issues.
MICHAEL L. SALGALLER, PHD
Director Invention Development and Marketing Unit (IDMU), NCI
Dr. Michael Salgaller leads the Invention Development and Marketing Unit (IDMU) within the National Cancer Institute’s (NCI’s) Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support technology development and commercialization. The IDMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NCI (as well as NIH in general). Immediately prior to returning to the NCI, Michael was a Vice President at The Conafay Group, a healthcare-focused government affairs firm in downtown DC, where he led alliance development activities centered on civilian health. He served as President of Biologics Consulting Group, a boutique firm providing professional services focused on regulatory affairs. Michael spent several years on the investment team of an early-stage venture capital firm dedicated to the life sciences. He began his buy-side career as Vice President of R&D for Northwest Biotherapeutics, where he led the development of cancer cell therapies that achieved clinical benefit. He began his career as a Senior Scientist with Dr. Steve Rosenberg at the NCI. He is the author of “Biotechnology Entrepreneurship,” and teaches an entrepreneurship class at NIH. He is on the Board of Canines-N-Kids, a foundation supporting cooperation between researchers in pediatric and veterinary oncology. He has written over 70 scientific/business articles and book chapters. Dr. Salgaller received his PhD in Pathology from The Ohio State University.
PAM SHARMA, MD, PHD
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson
Padmanee Sharma is a professor of Genitourinary Medical Oncology and Immunology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. She has participated in 54 research outputs since 1996, focusing primarily on immunotherapy in her collaborations with Dr. James P. Allison. Sharma is a Cancer Research Institute Investigator who has tested new prostate cancer immunotherapies, looking for differences in T cell subsets and function between pre-therapy blood and tissue samples versus post-therapy blood and tissue samples. She has won multiple awards during her career including the 2012 MD Anderson Cancer Center Faculty Scholar Award and the 2008 Melanoma Research Alliance Young Investigator Award. With Allison, Sharma is exploring combinations of immunological therapies and targeted drugs in preclinical studies to more effectively treat a variety of cancers.
LYNDA CHIN, MD
CEO, Apricity Health
Founder, Department of Genomic Medicine, MD Anderson
An elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in the application of analytical technologies, AI/ML, and big data in medicine. Her groundbreaking work synthesizing terabyte-scale datasets in genomics and oncology research has opened new frontiers in digital medicine.
As founding chair of the Department of Genomic Medicine at the University of Texas MD Anderson Cancer Center, Dr. Chin launched projects to transform workflows for patient-oriented research harness high-velocity clinical and research data, and democratize cancer care expertise across a network of global partner care centers. As Chief Innovation Officer of the University of Texas System, she forged initiatives to create infrastructure for more equitable access to care for underserved populations. In her work at The Cancer Genome Atlas (TCGA), she was Principal Investigator driving development of the Firehose data pipeline, served on the Scientific Steering Committee of the International Cancer Genome Consortium (ICGC), and is actively involved in conceptualizing the next phase of ICGC, ICGC-ARGO (Accelerating Research on Genomic Oncology).
Dr. Chin earned a B.A. degree from Brown University and a M.D. degree from Albert Einstein College of Medicine. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and Montefiore Medical Center in NY and went on to a productive academic research career at Dana-Farber Cancer Institute, where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard.
DR. BRIAN LEYLAND JONES
Former Director of Emory and McGill Cancer Centers
CMO National Foundation for Cancer Research
Chief Science Officer, The Darwin Foundation
Brian Leyland-Jones, BSc (Ist class Hons), MB BS, PhD, FRACP, FRCPC is the Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR) and Chief Scientific Officer of The Darwin Foundation. He also serves as the Chief Medical Officer of OTraces, Xylonix and the N OF 1 Mission, collectively devoted to the implementation of prevention and cure of malignancy globally. He sits on several national and international boards including the Asian Foundation for Cancer Research (AFCR), NED Biosystems, Non-Pareil, Ratio and is Director Emeritus for the WIN Consortium. He founded Xanthus, AKESOgen and Viviphi.
Dr. Leyland-Jones holds biochemistry, medical, and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew’s and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in Early Phase clinical, clinical pharmacological and biomarker evaluation of many anticancer compounds, including the platinums and anthracycline analogs in use today. In 1983, he moved to the National Cancer Institute (NCI) to head the Developmental Chemotherapy section. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in-vitro screening to Phase III clinical trials, including overseeing the early development of paclitaxel in Phase 1 and 2 trials. From 1990 to 2000, he served as founding chair of Oncology and director of the McGill University Comprehensive Cancer Centre. He recruited and built a broad multifaceted cancer centre, including a robust cross-hospital clinical trials enterprise, with deep clinical pharmacologic and biomarker support. Dr. Leyland-Jones continued as the Minda de Gunzberg Chair in Oncology and professor of medicine at McGill University in Montreal, Canada for 7 additional years, focusing on the development and biomarker strategies of several of the new targeted oncologic agents.
He joined Emory University in 2007. As Director of the Winship Cancer Centre and Associate Vice-President of Health Sciences, Dr. Leyland-Jones lead the Centre to obtain National Cancer Institute Cancer Centre Designation, the first in the State of Georgia, and for the first time in 30 years. Dr. Leyland-Jones was instrumental in building the Genomics Medicine Program at the Avera Cancer Institute in Sioux Falls, SD where he was the Vice President of Molecular and Experimental Medicine from 2014-2019. Dr. Leyland-Jones’ principal academic contributions have been in the fields of anticancer therapy development, the pharmacodynamics, pharmacokinetics, and pharmacogenetics of oncological clinical trials, the translation of preclinical models into the clinic, biomarker endpoints in Phase I/II clinical trials, and screening and mechanistic studies of novel targeted and chemotherapeutic anticancer agents.
Dr. Leyland-Jones is the recipient of numerous research grants, and has served as principal, co-principal and co-investigator on more than 100 clinical studies. He has authored and co-authored more than 210 peer-reviewed articles and book contributions, 25 books and book chapters, 425 abstracts and 35 patents. He has a robust speaking and private consulting practice that takes him all over the world.
DR. ALFRED SLANETZ
CEO, Geneius Biotechnology
Former CEO, Bluebird Bio
Former Head of Product Development, Genetech
Dr. Slanetz is the founder of Geneius Biotechnology and has been President, Chief Executive Officer and a director of the Company full time since its inception. Prior to co-founding the Company, he served as Chief Executive Officer and President of Bluebird Bio.
Dr. Slanetz also served as Vice President, Business Development of TRANSGENE in May 1996. From 1994 to 1996, he served as Manager, New Product Planning and Development at Genentech Inc. Prior to that, Dr. Slanetz was a Management Consultant for Arthur D. Little.
He received his Ph.D. in Molecular and Immunobiology from Yale University, as well as a Masters from Brown University.
Chief Science Officer, Foundation Medicine
Former Director of Disease and Biomarker Transcriptomics at GlaxoSmithKline
Priti Hegde, Ph.D., joined Foundation Medicine as the Chief Scientific Officer in August 2019. Dr. Hegde oversees clinical product development, cancer genomics, and early-stage research, as well as regulatory and quality assurance, to accelerate advancement of the Company’s leading comprehensive genomic profiling portfolio. She is passionate about innovation in cancer research and translating innovations to precision medicine tools to advance care for patients.
Dr. Hegde has spent nearly two decades in the biopharmaceutical industry, with a proven track record in drug development, registration, and commercialization of therapeutics with companion diagnostics in cancer immunotherapy.
Prior to joining Foundation Medicine, Dr. Hegde spent 12 years at Genentech, a member of Roche Group, where she held roles of increasing responsibility. Most recently, Dr. Hegde served as senior director and principal scientist in oncology biomarker development at Genentech, during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy. Dr. Hegde was instrumental in the approvals for atezolizumab in both the United States and European Union, as well as its forthcoming diagnostic filings.
Before joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. Dr. Hegde completed her post-doctoral fellow at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy from Mumbai University, India.
Former Head of Complex Manufacturing, Merck
Chief Technology and Manufacturing Officer for Swan Bio
Dr. Froland is the current Chief Technology and Manufacturing Officer for Swan Bio.
He is a first-principles biochemist with twenty years’ industry experience that has led innovative development organizations, small and large, across the entire biopharmaceutical product development spectrum from early clinical development through to global registration and successful product launches. Froland has deep experience in biologics evaluation, product maturation, formulation, drug product image and manufacturing process development, characterization and qualification in support of production of biopharmaceutical drug substance and drug product.
Dr. Froland was most recently Associate Vice President at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization and manufacturing strategy. He has previously worked at Calypte Biomedical, Questcor Pharmaceuticals, Bayer Pharmaceuticals and Aerovance. Dr. Froland is the co-inventor on three patents related to synthesis of therapeutic peptides and has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology. He received his Ph.D. in Biochemistry from the University of Minnesota Medical School and conducted post-doctoral research at the Department of Chemistry, University of California, Berkeley.
DR. SUNG POBLETE
CEO, Stand Up To Cancer
Sung Poblete, PhD, RN has made it her life’s work to fight cancer from all angles: galvanizing awareness, improving patient outcomes, and enabling cutting-edge research. Today, she is chief executive officer of Stand Up To Cancer (SU2C).
A common thread throughout Poblete’s career has been her dedication to cutting-edge innovation on the research front, paired with a steadfast focus on improving nonprofit and corporate healthcare.
Previously, Poblete was director of clinical and translational programs at the American Association for Cancer Research (AACR), the scientific partner of SU2C, where she spearheaded the organization’s scientific review, oversaw grants administration and management, and served as the primary liaison for scientific communications and general administration. Pivotal to the organization’s collaborations, she was liaison to the Clinical and Translational Committee, the Pediatric Cancer Working Group, the Task Force on Survivorship Research, the Oncology Nursing Society, and the American Society of Clinical Oncology, all while leading AACR’s continuing medical education program.
Poblete has also held senior-level positions focused on patient outcomes and disease management. Notably, as vice president of clinical operations for a subsidiary of Fresenius Medical Care North America, she developed and ran national chronic kidney disease management programs. As executive director of the Oxford Health Plans Foundation, she facilitated grants that furthered research and programs aimed at improving health care delivery.
Poblete has received grants from the Centers for Disease Control and Prevention, National Institutes of Health, National Science Foundation, and private foundations. She also served as a Centers for Disease Control and Prevention–UC Health Systems Public Scholar from 1999 to 2000. She currently serves on the Executive Board of the Osteosarcoma Institute and on the Stand Up To Cancer – Canada Board of Directors.
She earned her bachelor of science degree, master of science degree, and PhD in nursing from Rutgers, where she also began her teaching career 20 years ago. She continues to serve Rutgers as a visiting professor at the School of Nursing. In 2016, Dr. Poblete was inducted into Rutgers Hall of Distinguished Alumni.
Partner, ATEM Capital
Anton Gopka is a CEO and General Partner at ATEM Capital managing an evergreen US Biotech Fund - Health Square Fund.
Prior to ATEM Mr. Gopka was managing one of the largest Russia-based biotechnological venture capital funds — a strategic partnership between RUSNANO and Domain Associates. From October 2010 to April 2011, Mr. Gopka was a vice president for mergers and acquisitions at Barclays Capital, LLC, a subsidiary of Barclays PLC. Prior to Barclays Capital, from October 2008 to October 2010, he was director of mergers and acquisitions at Sistema JSFC, the largest diversified conglomerate in Russia. From April 2006 to October 2008, Mr. Gopka worked at Dresdner Kleinwort Limited, an investment bank, where he advised on a number of M&A and capital markets transactions.
Mr. Gopka serves on the board of directors of many healthcare companies, including Regado BioSciences, Inc., CoDa Therapeutics, Inc., Lithera, Inc., Tragara Pharmaceuticals, Inc. and NovaDigm Therapeutics, Inc.
Mr. Gopka received a masters degree in international economics from the Moscow State University for International Affairs. He also earned a corporate finance course diploma from INSEAD.
Founder, Catalytic Impact Foundation
Partner, Easton Capital
Richard Lipkin is a Managing Director of New York-based Easton Capital Investment Group. Previously, he was a partner of Commerce Health Ventures, a life sciences healthcare fund, and Laird & Co., a private merchant bank; a biotech analyst consultant for a Goldman Sachs hedge fund and for DARPA; Executive Director of the Strang Cancer Prevention Center; and a prolific author, awarded the American Chemical Society’s Grady-Stack Award for research analysis.
Mr. Lipkin studied theoretical neuroscience at Columbia University, and serves on many boards, councils, and committees for the Weizmann Institute of Science, Rockefeller and Columbia Universities, MBL, the New York Academy of Science, and Montefiore Medical Center.
Mr. Lipkin is an honors graduate of Princeton University, holds an MBA from Columbia University, and is a Senior Staff Associate in Columbia University’s Department of Neuroscience.
DR. PHILIP FRIEDLANDER
Professor, Medicine, Hematology and Medical Oncology
Dr. Friedlander received medical school training at Columbia University where he obtained his M.D. and Ph.D. degree in Biology. He remained at Columbia Presbyterian Medical Center to complete his postdoctoral training in Internal Medicine and subsequently completed a clinical fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. He then joined the faculty of the Dana Farber Cancer Institute/Brigham and Women’s Hospital as an attending physician within the Melanoma and Cutaneous Oncology Programs and as an Instructor of Medicine at Harvard Medical School.
His clinical interests include the development of targeted therapies and immunotherapies for patients with melanoma, merkel cell carcinoma, advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and sebaceous gland tumors. At the Dana Farber Cancer Institute he acted as a principal investigator testing novel therapeutic approaches for melanoma including PARP inhibition, hsp90 inhibition, anti-apoptotic approaches, and immune modulatory and anti-CTLA4 based strategies. He investigated in non-melanoma skin cancers novel therapeutic strategies such as hedgehog signaling pathway inhibition in advanced basal cell carcinoma.
As a member of the Division of Hematology/Medical Oncology and as the Director of the Melanoma Medical Oncology Program at Mount Sinai, he will be caring for patients with cutaneous malignancies and continue working to develop collaborative translational and basic science projects and treatments for patients with cutaneous malignancies.
Infectious Disease Add-On Day Speakers
Director General, International Vaccine Institute
Jerome H. Kim, MD is the Director General of the International Vaccine Institute (IVI). Dr. Kim led the US Army’s RV144 HIV vaccine trial in Thailand, the first demonstration that an HIV vaccine could prevent human infection and subsequent work identifying immunological and virological correlates. He rose to become the Principal Deputy, US Military HIV Research Program, and Project Manager, HIV Vaccines, US Army Medical Materiel Development Agency.
In 2015 he retired from the US Army and became the 3d Director General of the International Vaccine Institute (IVI). The IVI was founded in 1997 and is the first international organization headquartered in the Republic of Korea. It counts 35 signatory countries and the World Health Organization as supporters. The IVI’s 130 employees work to accelerate R&D in vaccines for Global Health in over 30 countries with collaborators from Korea, Asia and around the world. During Dr. Kim’s tenure IVI’s oral cholera vaccine, produced by a Korean company (EuBiologics), was prequalified, and EuBiologics production of Euvichol has contributed greatly to the worldwide surge in OCV use to prevent cholera. Collaboration with the Bill & Melinda Gates Foundation, SK Chemicals (Korea) and BioFarma (Indonesia) have brought IVI’s new typhoid conjugate vaccine to Phase II testing. IVI has been critical in generating much needed information on the burden and cost of typhoid (enteric fever) worldwide through the Gates-funded TSAP and SETA programs. IVI’s laboratory is working on new vaccines against Shigella, Salmonella, tuberculosis, the Middle East Respiratory Syndrome, hepatitis A, and adenovirus. IVI’s $30M annual budget comes from state funders (Korea, Sweden, India), philanthropies (Bill and Melinda Gates Foundation, Samsung Life Public Welfare Foundation, Wellcome Trust), US NIH, the European and Developing Countries Clinical Trials Partnership, and Korean private donors through the Korea Support Committee for IVI.
The author of over 250 publications and 11 patents, Dr. Kim graduated with highest honors in Biology and high honors in History from the University of Hawaii, where he won the Arthur Lyman Dean Prize in the Humanities and the Library Prize for Pacific Islands Area Research. He then attended the Yale University School of Medicine and trained in Internal Medicine and Infectious Diseases at Duke University Medical Center. He became a full Professor of Medicine at the Uniformed Services University of the Health Sciences in 2012. Since leaving the military Dr. Kim became an adjunct Professor in the Department of Medicine, Uniformed Services University of the Health Sciences, the Graduate School of Public Health, Seoul National University, and Yonsei University. In addition to several honor societies, including Phi Beta Kappa and Alpha Omega Alpha, in 2013 he received the John Maher Award for Research Excellence, USUHS, and the Department of the Army R&D Achievement Award for Technical Excellence. Dr. Kim is a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He has been listed among the 50 most influential persons in vaccines and serves on scientific advisory groups to private and public organizations, the World Health Organization, and Gavi, the Vaccine Alliance.
Founding Director of the Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine
Former Director of Global Immunisation Communication at UNICEF
Professor of Anthropology, Risk and Decision Science
Author of STUCK: How Vaccine Rumors Start – and Why They Don’t Go Away
Heidi J. Larson, PhD, is Professor of Anthropology, Risk and Decision Science and is the Founding Director of the Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine. She is also Clinical Professor of Health Metrics Sciences, University of Washington, Seattle, USA, and Guest Professor at the University of Antwerp, Belgium.
Dr. Larson previously headed Global Immunisation Communication at UNICEF, chaired GAVI’s Advocacy Task Force, and served on the WHO SAGE Working Group on vaccine hesitancy. The VCP is a WHO Centre of Excellence on addressing Vaccine Hesitancy.
Professor Larson’s research focuses on the analysis of social and political factors that can affect uptake of health interventions and influence policies. Her particular interest is on risk and rumour management from clinical trials to delivery – and building public trust. She served on the FDA Medical Countermeasure (MCM) Emergency Communication Expert Working Group, and is currently Principal Investigator for a global study on acceptance of vaccination during pregnancy; an EU-funded (EBODAC) project on the deployment, acceptance and compliance of an Ebola vaccine trial in Sierra Leone; and a global study on Public Sentiments and Emotions Around Current and Potential Measures to Contain and Treat COVID-19.
She is author of STUCK: How Vaccine Rumors Start – and Why They Don’t Go Away
Team Lead, Technology Transfer & Intellectual Property Office (TTIPO) · National Institute of Allergy and Infectious Diseases (NIAID)
Wade is a seasoned technology transfer professional with over ten (10) years’ experience in
academic and federal technology transfer offices in positions of increasing responsibility. Wade
received a Ph.D. in Microbiology from the University of Chicago, and a B.S./M.S. in Microbiology
from Michigan State University, East Lansing, MI then worked as a post-doctoral researcher
studying the pathogenesis of B. anthracis at the University of Texas Health Science Center –
Houston. Following his work as a bench scientist, Wade joined the technology transfer office at
the University of Chicago and started his career as a technology transfer profession. Wade is a
registered Patent Agent with the USPTO and is a long-standing member of AUTM and LES.
DR. PAUL MARIK
Chief, Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School
Founding Member, Front Line Covid-19 Critical Care Alliance (FLCCC)
Professor of Medicine, Eastern Virginia Medical School
Dr Marik received his medical degree from the University of the Witwatersrand, Johannesburg, South Africa. He was an ICU attending at Baragwanath Hospital, in Soweto, South Africa. During this time he obtained a Master of Medicine Degree, Bachelor of Science Degree in Pharmacology, Diploma in Anesthesia as well as a Diploma in Tropical Medicine and Hygiene. Dr Marik did a Critical Care Fellowship in London, Ontario, Canada, during which time he was admitted as a Fellow to the Royal College of Physicians and Surgeon of Canada. Dr Marik has worked in various teaching hospitals in the US since 1992. He is board certified in Internal Medicine, Critical Care Medicine, Neurocritical Care and Nutrition Science. Dr Marik is currently Professor of Medicine and Chief of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School in Norfolk, Virginia. Dr Marik has written over 400 peer reviewed journal articles, 50 book chapters and authored four critical care books.